CELGENE CORPORATION for CELGENE CORPORATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK GLIHA | — |
Health Issues HCR
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREG CHESMORE | — |
| PATRICK GLIHA | — |
| STEPHEN RUBRIGHT | — |
| MATTHEW SCHUMAKER | — |
| ALANNA TEMME | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.